Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shH1
- Development stage
- Preclinical
- Lead developer
- Doshisha Women's College of Liberal Arts
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
shH1 is a short hairpin RNA (shRNA) candidate identified through a high-throughput shRNA screening system designed to detect agents that induce epithelialization (mesenchymal-to-epithelial transition, or MET) in mesenchymal cancer stem-like cells (CSLCs). Developed by researchers at Doshisha Women's College of Liberal Arts, shH1 has been shown to reverse the epithelial-mesenchymal transition (EMT) in mesenchymal breast cancer cells (such as MDA-MB-231) and glioblastoma cells. In addition to inducing epithelialization, shH1 strongly inhibits the growth of these cancer cells, suggesting its sequence-specific mechanism has therapeutic potential as a nucleic acid-based oncology treatment.
Beyond the preview
Go deeper on shH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shH1.